These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 16847455

  • 1. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
    Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC, Iozzo RV.
    Oncogene; 2007 Jan 18; 26(3):368-81. PubMed ID: 16847455
    [Abstract] [Full Text] [Related]

  • 2. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
    Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, Henriksson R, Hedman H.
    Exp Cell Res; 2011 Feb 15; 317(4):504-12. PubMed ID: 21087604
    [Abstract] [Full Text] [Related]

  • 3. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
    Xiao Q, Tan Y, Guo Y, Yang H, Mao F, Xie R, Wang B, Lei T, Guo D.
    PLoS One; 2014 Feb 15; 9(10):e111419. PubMed ID: 25353163
    [Abstract] [Full Text] [Related]

  • 4. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity.
    Iyer AK, Tran KT, Borysenko CW, Cascio M, Camacho CJ, Blair HC, Bahar I, Wells A.
    J Cell Physiol; 2007 Jun 15; 211(3):748-58. PubMed ID: 17311283
    [Abstract] [Full Text] [Related]

  • 5. LRIG1 expression in colorectal cancer.
    Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y, Hedman H, Henriksson R, Malmer B.
    Acta Oncol; 2007 Jun 15; 46(8):1118-22. PubMed ID: 17851870
    [Abstract] [Full Text] [Related]

  • 6. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
    Park SY, Yoon SJ, Freire-de-Lima L, Kim JH, Hakomori SI.
    Carbohydr Res; 2009 Aug 17; 344(12):1479-86. PubMed ID: 19559406
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
    Adams TE, Koziolek EJ, Hoyne PH, Bentley JD, Lu L, Lovrecz G, Ward CW, Lee FT, Scott AM, Nash AD, Rothacker J, Nice EC, Burgess AW, Johns TG.
    Growth Factors; 2009 Jun 17; 27(3):141-54. PubMed ID: 19333814
    [Abstract] [Full Text] [Related]

  • 9. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein.
    Viklund L, Loo BM, Hermonen J, El-Darwish K, Jalkanen M, Salmivirta M.
    Biochem Biophys Res Commun; 2002 Jan 11; 290(1):146-52. PubMed ID: 11779146
    [Abstract] [Full Text] [Related]

  • 10. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, Zumpano R, Belfiore A, Andò S, Maggiolini M.
    Int J Biochem Cell Biol; 2009 Mar 11; 41(3):603-14. PubMed ID: 18692155
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.
    Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM.
    Exp Cell Res; 2008 Oct 01; 314(16):2907-18. PubMed ID: 18687326
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
    O'Rourke DM, Nute EJ, Davis JG, Wu C, Lee A, Murali R, Zhang HT, Qian X, Kao CC, Greene MI.
    Oncogene; 1998 Mar 05; 16(9):1197-207. PubMed ID: 9528862
    [Abstract] [Full Text] [Related]

  • 18. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
    Holbrook MR, Slakey LL, Gross DJ.
    Biochem J; 2000 Nov 15; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
    [Abstract] [Full Text] [Related]

  • 19. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways.
    Joo CK, Kim HS, Park JY, Seomun Y, Son MJ, Kim JT.
    Oncogene; 2008 Jan 24; 27(5):614-28. PubMed ID: 17637750
    [Abstract] [Full Text] [Related]

  • 20. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells.
    Murayama Y, Shinomura Y, Oritani K, Miyagawa J, Yoshida H, Nishida M, Katsube F, Shiraga M, Miyazaki T, Nakamoto T, Tsutsui S, Tamura S, Higashiyama S, Shimomura I, Hayashi N.
    J Cell Physiol; 2008 Jul 24; 216(1):135-43. PubMed ID: 18247373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.